1. Home
  2. BZFD vs TENX Comparison

BZFD vs TENX Comparison

Compare BZFD & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BZFD

BuzzFeed Inc.

N/A

Current Price

$0.50

Market Cap

85.0M

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.70

Market Cap

74.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BZFD
TENX
Founded
2006
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.0M
74.1M
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
BZFD
TENX
Price
$0.50
$1.70
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $9.63
AVG Volume (30 Days)
207.2K
★ 2.0M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $185,266,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$108.07
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.54
$1.31
52 Week High
$2.21
$19.40

Technical Indicators

Market Signals
Indicator
BZFD
TENX
Relative Strength Index (RSI) 16.07 42.61
Support Level N/A $1.34
Resistance Level $0.83 $2.01
Average True Range (ATR) 0.07 0.14
MACD -0.04 0.05
Stochastic Oscillator 5.62 40.20

Price Performance

Historical Comparison
BZFD
TENX

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: